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1. INTRODUCTION {#ardp201800330-sec-0010}
===============

Coronaviruses (CoVs) are a large family of enveloped RNA viruses with positive‐sense single‐stranded RNA genome, affecting a wide range of animal species. Some widely spread human coronaviruses (HCoVs, i.e., strains 229E, OC43, NL63, and HKU1) are the etiologic agents in 15--30% of common cold disease,[1](#ardp201800330-bib-0001){ref-type="ref"} a relatively benign yet highly contagious respiratory illness that can possibly be complicated by virus‐induced asthma or exacerbations of chronic obstructive pulmonary disease.[2](#ardp201800330-bib-0002){ref-type="ref"} These HCoVs can also cause high‐morbidity lower respiratory tract conditions, such as pneumonia, bronchiolitis, and croup, especially in immunocompromised patients, the elderly and young children.[3](#ardp201800330-bib-0003){ref-type="ref"}, [4](#ardp201800330-bib-0004){ref-type="ref"}, [5](#ardp201800330-bib-0005){ref-type="ref"} Besides, two highly pathogenic CoVs originating from animal reservoirs have had a major medical and socio‐economic impact. In 2003, the newly discovered SARS‐CoV[6](#ardp201800330-bib-0006){ref-type="ref"} responsible for the severe acute respiratory syndrome, suddenly emerged in South‐East Asia, after which it caused 8096 infections worldwide with a case‐fatality (CFR) rate of 9.6% and a total societal cost estimated at 40 billion USD.[7](#ardp201800330-bib-0007){ref-type="ref"} In 2012, the thus far unknown Middle East Respiratory Syndrome virus (MERS‐CoV) appeared[6](#ardp201800330-bib-0006){ref-type="ref"} which, to date, caused 2249 cases with a CFR of 36%.[8](#ardp201800330-bib-0008){ref-type="ref"} The high virulence of SARS‐ and MERS‐CoVs, combined with their sudden emergence and clear pandemic potential, has boosted the development of preventive (i.e., vaccines) or therapeutic (i.e., antiviral drugs) interventions to address serious CoV infections in humans. Thus far, except for quarantine measures, no effective intervention exists.

In our laboratory, we initiated a small‐molecule screening program in HCoV‐infected cells, aimed at identifying new chemical entities and CoV targets with relevance for antiviral drug development. In the present report, we describe the identification of a new class of CoV inhibitors carrying a 1‐thia‐4‐azaspiro\[4.5\]decan‐3‐one scaffold (Scheme [1](#ardp201800330-fig-0001){ref-type="fig"}). A series of structural analogs were chemically synthesized to delineate the structure‐activity relationship. Intriguingly, the same scaffold is present in a class of H3 hemagglutinin‐specific influenza virus fusion inhibitors that was discovered by our team some time ago.[9](#ardp201800330-bib-0009){ref-type="ref"} This points to the 1‐thia‐4‐azaspiro\[4.5\]‐decan‐3‐one scaffold as a versatile chemical structure with high relevance for antiviral drug development.

![Synthetic route and chemical structures for compound series **7** and **8**](ARDP-352-1800330-g001){#ardp201800330-fig-0001}

2. RESULTS AND DISCUSSION {#ardp201800330-sec-0020}
=========================

2.1. Chemistry {#ardp201800330-sec-0030}
--------------

Hydrazides (**3**, **4**) were obtained by stepwise reactions, firstly by esterification of acids in methanol in the presence of H~2~SO~4~ to give esters (**1**, **2**), and secondly hydrazinolysis of **1**, **2** to give **3**, **4**.[10](#ardp201800330-bib-0010){ref-type="ref"} **3**, **4** were reacted with cyclic ketones to afford corresponding derivatives **5**, **6** that are commercially available or recorded earlier, except **5a** and **6a**.[11](#ardp201800330-bib-0011){ref-type="ref"}, [12](#ardp201800330-bib-0012){ref-type="ref"} Spectral and analytical data of **5a** and **6a** are given under "General procedure for the synthesis of *N\'*‐(cycloalkylidene)‐2‐phenoxyacetohydrazides (**5**) or *N*\'‐(cycloalkylidene)‐3‐phenylpropanehydrazides (**6**)". Cyclocondensation of **5** or **6** with sulphanylacetic acid or 2‐sulphanylpropanoic acid led to *N*‐(substituted 3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]non‐4‐yl/\[4.5\]dec‐4‐yl/\[4.6\]undec‐4‐yl)‐2‐phenoxyacetamide (**7**) or *N*‐(substituted 3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]non‐4‐yl/\[4.5\]decan‐4‐yl)‐3‐phenylpropanamides (**8**). The first evidence for the formation of **7** and **8** was the observation of a new band between 1728--1697 cm^−1^ in their IR spectra due to 3‐carbonyl group. The C=O stretching band of the carboxamide moiety was also observed at 1660--1693 cm^−1^. Bands between 3468--3167 cm^−1^ region confirmed the presence of NH stretching bands. In the ^1^H‐NMR spectra of **7**, CONH protons were observed at δ 9.91--10.59 ppm as singlets. C~2~--methylene protons of **7a--g** and **8a--h** resonated at δ 3.52--3.64 ppm as singlets, while C~2~‐methine protons of **7h--n** and **8i--p** gave quartets at δ 3.80--3.93 ppm. The ^13^C‐NMR spectra of **7a--m** and **8j** showed spirothiazolidinone C~2~ carbon (δ 27.76--38.08 ppm) and spirothiazolidinone C=O carbon (δ 167.59--170.77 ppm) resonances as another evidence for the formation of a ring system. Molecular weights (for the group coded as **7**) were verified by taking mass spectra to get another proof. ESI method was applied in positive or negative modes and \[M+H\]^+^ or \[M‐H\]^−^ ions formed confirmed the molecular weights.

2.2. Biological activity {#ardp201800330-sec-0040}
------------------------

The compounds were evaluated for antiviral activity against human coronavirus 229E in HEL 299 fibroblast cells, and against influenza A/H1N1, A/H3N2, and B viruses in MDCK cells. The test compounds can be classified in either Group **7**, carrying a phenoxyethyl side chain, or Group **8**, with a phenethyl side chain. Our previously discovered H3 hemagglutinin‐specific influenza virus fusion inhibitors[9](#ardp201800330-bib-0009){ref-type="ref"} have the same scaffold but carry an imidazo\[2,1‐b\]thiazole or *o*‐hydroxyphenyl side chain. The current series of molecules show no activity against influenza viruses at concentrations up to 100 µM (data not shown), probably phenoxymethyl and phenethyl side chains are not suitable for binding to influenza virus hemagglutinin.

Seven compounds, i.e. **7m**, **7n**, **8k**, **8l**, **8m**, **8n**, and **8p**, were found to inhibit human coronavirus 229E with low cytotoxicity (Table [1](#ardp201800330-tbl-0001){ref-type="table"}). The compounds showing activity all carry a methyl substituent at the C‐2 position of the azaspiro\[4.5\]decane (R~1~), whereas the unmethylated analogs (i.e., **7e**, **7f**, **8c**, **8d**, **8e**, **8f**, **8h**) were devoid of antiviral activity. The same observation was previously made for the structurally related influenza virus fusion inhibitors.[9](#ardp201800330-bib-0009){ref-type="ref"} In addition, for compound series **8**, the anti‐coronavirus activity clearly depended on the bulkiness of the C‐8 substituent of the azaspiro\[4.5\]decane (R). No activity was seen for the unsubstituted compound **8j** (R = H). Intermediate activity was observed for **8k** and **8l** (EC~50~ = 28 and 18 µM), which carry a 4‐methyl and 4‐ethyl‐group, respectively. A further increase in activity was seen for **8m**, **8n**, and **8p** (EC~50~ values 5.5--8.1 µM), carrying, respectively, a 4‐propyl, 4‐*tert*‐butyl and 4‐phenyl group. An exception here is **8o** (R = 4‐CF~3~), which did not show antiviral activity at concentrations up to 100 µM. Its direct analog belonging to Group 7 (**7m**) however, was moderately active (EC~50~ = 31 µM), and so was **7n** (EC~50~ = 12 µM), which carries the same substituent (4‐phenyl) as **8p**. Molecules **7k** and **7l**, which are the counterparts of **8k** and **8n**, were not active.

###### 

Activity in human coronavirus 229E‐infected HEL[^a^](#ardp201800330-tbl1-note-0002){ref-type="fn"} cells

  Compounds   Antiviral activity (EC~50~ [^b^](#ardp201800330-tbl1-note-0003){ref-type="fn"})   Cytotoxicity (MCC[^c^](#ardp201800330-tbl1-note-0004){ref-type="fn"})
  ----------- --------------------------------------------------------------------------------- -----------------------------------------------------------------------
  **7a**      \>100                                                                             \>100
  **7b**      \>100                                                                             \>100
  **7c**      \>100                                                                             \>100
  **7d**      \>100                                                                             ≥100
  **7e**      \>100                                                                             \>100
  **7f**      \>100                                                                             \>100
  **7g**      \>100                                                                             \>100
  **7h**      \>100                                                                             \>100
  **7i**      \>100                                                                             \>100
  **7j**      \>100                                                                             \>100
  **7k**      \>100                                                                             \>100
  **7l**      \>100                                                                             \>100
  **7m**      31 ± 1                                                                            \>100
  **7n**      12 ± 1                                                                            100
  **8a**      \>100                                                                             \>100
  **8b**      \>100                                                                             \>100
  **8c**      \>100                                                                             \>100
  **8d**      \>100                                                                             \>100
  **8e**      \>100                                                                             \>100
  **8f**      \>100                                                                             \>100
  **8g**      \>100                                                                             \>100
  **8h**      \>100                                                                             100
  **8i**      \>100                                                                             \>100
  **8j**      \>100                                                                             \>100
  **8k**      28 ± 0                                                                            \>100
  **8l**      18 ± 5                                                                            ≥100
  **8m**      8.1 ± 2.2                                                                         100
  **8n**      5.5 ± 0.7                                                                         ≥100
  **8o**      \>100                                                                             \>100
  **8p**      6.1 ± 0.2                                                                         50
  **K22**     3.3 ± 1.0                                                                         50

Data represent the averages ± SEM of 3--4 independent tests.

HEL: human embryonic lung fibroblast cells.

EC~50~: compound concentration (µM) producing 50% inhibition of virus replication, as determined by microscopic scoring of the cytopathic effect (CPE).

MCC: minimum cytotoxic concentration (µM), that is, compound concentration producing minimal changes in cell morphology, as estimated by microscopy.
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3. CONCLUSION {#ardp201800330-sec-0050}
=============

We report the chemical synthesis of a compound series with 4‐carboxamido‐3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]nonan/\[4.5\]decan/\[4.6\]undecan structure. Upon evaluation in virus‐infected cell culture assays, seven compounds proved to be able to inhibit human coronavirus 229E virus replication, with the most potent analog having an EC~50~ value of 5.5 µM. The anti‐coronavirus activity was found to be strongly dependent on the substituents at the C‐2 and C‐8 positions of the azaspiro\[4.5\]decane scaffold. While a series of closely related analogs was previously demonstrated to target influenza virus fusion by interfering with hemagglutinin refolding at low pH, the present molecules have no activity against human influenza A/H1N1, A/H3N2, and B viruses. Ongoing mechanistic investigations will reveal the biochemical basis for their inhibitory effect on coronavirus.

4. EXPERIMENTAL {#ardp201800330-sec-0060}
===============

4.1. Chemistry {#ardp201800330-sec-0070}
--------------

### 4.1.1. General {#ardp201800330-sec-0080}

Melting points were determined in open capillary tubes with a Büchi B‐540 melting point apparatus and are uncorrected. IR spectra were recorded in KBr disks on a Shimadzu IR Affinity‐1 FTIR spectrophotometer. ^1^H and ^13^C‐NMR spectra were recorded on Varian Unity Inova (500 MHz) and Varian Mercury (400 MHz) spectrophotometers. All chemical shifts were reported as δ (ppm) values and spin‐spin couplings (*J*) were expressed in Hz. Microanalyses were performed on a Thermo Finnigan Flash EA 1112 elemental analyzer. Electrospray ionization (ESI)/MS were determined on Agilent 6460 TripQuad LC‐MS/MS and Waters 2695 Alliance Micromass ZQ LC/MS spectrometers.

The original spectra of the investigated compounds are provided as Supporting Information. The InChI codes of the investigated compounds together with some biological activity data are also provided as Supporting Information.

### 4.1.2. Synthesis of methyl phenoxyacetate (1) or methyl 3‐phenylpropanoate (2) {#ardp201800330-sec-0090}

A solution of phenoxyacetic acid (0.01 mol) or 3‐phenylpropionic acid (0.01 mol) and sulfuric acid (98%) (0.1 ml) in 50 ml of methanol was heated for 24 hr. The solution was neutralized with 0.01 mol of sodium bicarbonate solution, the mixture was extracted with diethyl ether and, after distillation of solvent, the ester was used without further purification.[10](#ardp201800330-bib-0010){ref-type="ref"}, [13](#ardp201800330-bib-0013){ref-type="ref"}

### 4.1.3. Synthesis of 2‐phenoxyacetohydrazide (3) or 3‐phenylpropane‐hydrazide (4) {#ardp201800330-sec-0100}

A mixture of **1** or **2** (0.01 mol), ethanol (50 ml), and hydrazine (0.0125 mol) was refluxed for 1 hr. The solid was filtered off, washed with cold water and used without recrystallization.[10](#ardp201800330-bib-0010){ref-type="ref"}, [13](#ardp201800330-bib-0013){ref-type="ref"}

### 4.1.4. General procedure for the synthesis of *N\'*‐(cycloalkylidene)‐2‐phenoxyacetohydrazides (5) or *N\'*‐(cycloalkylidene)‐3‐phenylpropanehydrazides (6) {#ardp201800330-sec-0110}

A solution of hydrazide (**3** or **4**) and appropriate ketone (0.01 mol) in 20 ml of ethanol (96%) was refluxed for 1--3 hr and then the solution was allowed to cool. The solid thus formed was filtered off, dried and directly used in the next step.

#### *N\'*‐\[4‐(Trifluoromethyl)cyclohexylidene\]‐2‐phenoxyacetohydrazide (5a) {#ardp201800330-sec-0120}

Yield: 80%. mp: 140--142°C; IR (KBr) ʋ (cm^−1^): 3331, 3184, 3082 (N‐H), 1683 (C=O). ^1^H‐NMR (dimethyl sulfoxide \[DMSO\]‐*d* ~*6*~/400 MHz): 1.27--1.53 (2H, m, cyclohexane C~2,6‐ax~‐H), 1.86--2.10, 2.23--2.46, 2.51--2.72 (6H, 3m, C~2,6‐eq~‐H, C~3,5~‐H), 2.89, 3.05 (1H, 2d, *J* = 16 Hz, C~4~‐H), 4.59, 4.95 (2H, 2s, OCH~2~), 6.90--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.20--7.40 (2H, m, phenyl C~3,5~‐H), 10.45, 10.62 (1H, 2s, NH). ^13^C‐NMR (proton decoupled) (100 MHz) (DMSO‐*d* ~*6*~): 23.56, 24.01, 24.79, 25.03, 32.34, 32.45 (cyclohexane C~2,3,5,6~), 38.87--40.12 (C‐CF~3~ with (CD~3~)~2~SO), 64.70, 65.91 (OCH~2~), 114.35, 114.50, 114.69, 120.59, 121.01, 121.20, 129.33, 129.43 (phenyl C~2‐6~), 124.98 (q, ^2^ *J* ~C‐F~ = 277 Hz, CF~3~), 153.97, 157.70, 157.87, 158.18 (phenyl C~1~), 160.90, 163.97 (cyclohexane C~1~), 166.69, 169.29 (CO). (ESI+) MS *m/z* (%): 337 (\[M+Na\]^+^, 40), 315 (\[M+H\]^+^, 100). Anal. calcd. for C~15~H~17~ F~3~N~2~O~2~ (314.30): C: 57.32, H: 5.45, N: 8.91. Found: C: 57.19, H: 5.40, N: 8.94.

#### *N\'*‐\[4‐(Trifluoromethyl)cyclohexylidene\]‐3‐phenylpropanehydrazide (6a) {#ardp201800330-sec-0130}

Yield: 69%. mp: 117--120°C; IR (KBr) ʋ (cm^−1^): 3234, 3176 (N‐H), 1668 (C=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.28--1.47; 1.86--2.00; 2.23--2.41; 2.59--2.62 (9H, m, cyclohexane C~2‐6~‐H), 2.79--2.88 (4H, m, CH~2~), 7.15--7.29 (5H, m, phenyl C~2‐6~‐H), 10.17, 10.25 (1H, 2s, NH). Anal. calcd. for C~16~H~19~F~3~N~2~O (312.33): C: 61.53, H: 6.13, N: 8.97. Found: C: 61.60, H: 6.21, N: 9.12.

### 4.1.5. General procedure for the synthesis of *N*‐(substituted 3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]non‐4‐yl/\[4.5\]dec‐4‐yl/\[4.6\]undec‐4‐yl)‐2‐phenoxyacetamides (7) and *N*‐(substituted 3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]‐non‐4‐yl/\[4.5\]decan‐4‐yl)‐3‐phenylpropanamides (8) {#ardp201800330-sec-0140}

A mixture of **5** or **6** (0.005 mol) and sulfanylacetic acid or 2‐sulfanylpropanoic acid (1.5 ml) in 30 ml of dried toluene was refluxed for 4--10 hr, using a Dean Stark water separator. Toluene was evaporated *in vacuo*. The residue was neutralized with saturated sodium bicarbonate and was allowed to solidify. The crude product was filtered and recrystallized from ethanol or ethanol/water mixture.

#### *N*‐(3‐Oxo‐1‐thia‐4‐azaspiro\[4.4\]non‐4‐yl)‐2‐phenoxyacetamide (7a) {#ardp201800330-sec-0150}

Yield: 65%. mp: 113--117°C; IR (KBr) ʋ (cm^−1^): 3383, 3238 (N‐H), 1722 (C=O), 1687 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 1.52--1.62 (4H, m, spirononane C~7,8~‐H), 1.76, 1.95--2.07 (2H, 2H, dt, *J* = 13 Hz, 6 Hz, m, spirononane C~6,9~‐H), 3.64 (2H, s, spirononane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.95--6.99 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.32 (2H, m, phenyl C~3,5~‐H), 10.36 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 22.94 (spirononane C~7,8~), 29.17 (spirononane C~2~), 38.42 (spirononane C~6,9~), 66.49 (OCH~2~), 76.15 (spirononane C~5~), 115.23, 121.81, 129.89 (phenyl C~2‐6~), 158.01 (phenyl C~1~), 167.87 (NHCO), 168.13 (CO). (ESI+) MS *m/z* (%): 329 (\[M+Na\]^+^, 50), 307 (\[M+H\]^+^, 100), 233 (90). Anal. calcd. for C~15~H~18~N~2~O~3~S (306.38): C: 58.80, H: 5.92, N: 9.14. Found: C: 58.28, H: 6.43, N: 9.18.

#### *N*‐(7‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7b) {#ardp201800330-sec-0160}

Yield: 91%. mp: 78--80°C; IR (KBr) ʋ (cm^−1^): 3487, 3224 (O‐H/N‐H), 1714 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.62 (1H, qd, *J* = 13 Hz, 3 Hz, C~8‐ax~‐H), 0.83 (3H, d, *J* = 6 Hz, spirodecane C~7~‐CH~3~), 1.21--1.74 (8H, m, C~6~‐H, C~7~‐H, C~8‐eq~‐H, C~9~‐H and C~10~‐H), 3.56 (2H, s, spirodecane C~2~‐H), 4.69 (2H, s, OCH~2~), 6.95--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.32 (2H, m, phenyl C~3,5~‐H), 10.29 (1 H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 22.45 (spirodecane C~7~‐CH~3~), 22.83 (spirodecane C~9~), 28.35 (spirodecane C~2~), 29.92 (spirodecane C~7~), 33.06 (spirodecane C~8~), 36.73 (spirodecane C~10~), 45.39 (spirodecane C~6~), 66.41 (OCH~2~), 72.62 (spirodecane C~5~), 115.29, 121.80, 129.91 (phenyl C~2‐6~), 158.00 (phenyl C~1~), 167.84 (NHCO), 168.06 (CO). (ESI+) MS *m/z* (%): 357 (\[M+Na\]^+^, 50), 335 (\[M+H\]^+^, 100), 261 (40). Anal. calcd. for C~17~H~22~N~2~O~3~S.0.5H~2~O (343.43): C: 59.40, H: 6.70, N: 8.16. Found: C: 59.31, H: 6.36, N: 8.03.

#### *N*‐(8‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7c) {#ardp201800330-sec-0170}

Yield: 98%. mp: 122--124°C; IR (KBr) ʋ (cm^−1^): 3446, 3221 (N‐H), 1726 (C=O), 1681 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.83 (3H, d, *J* = 6 Hz, CH~3~), 1.03--1.22 (3H, m, spirodecane C~7‐ax~‐H, C~8~‐H and C~9‐ax~‐H), 1.63 (2H, d, *J* = 13 Hz, C~7,9‐eq~‐H), 1.66--1.75 (2H, m, C~6,10~‐H), 3.57 (2H, s, spirodecane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.95--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.32 (2H, m, phenyl C~3,5~‐H), 10.33 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/100 MHz): 21.76 (C~8~‐CH~3~), 27.76 (spirodecane C~2~), 30.38 (spirodecane C~8~), 31.28, 36.54 (spirodecane C~6,7,9,10~), 65.95 (OCH~2~), 71.99 (spirodecane C~5~), 114.77, 121.27, 129.38 (phenyl C~2‐6~), 157.56 (phenyl C~1~), 167.45 (NHCO), 167.59 (CO). (ESI−) MS *m/z* (%): 333 (\[M‐H\]^−^, 100), 259 (32). Anal. calcd. for C~17~H~22~N~2~O~3~S (334.43): C: 61.05, H: 6.63, N: 8.38. Found: C: 60.86, H: 6.56, N: 8.32.

#### *N*‐(8‐*tert‐*Butyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7d) {#ardp201800330-sec-0180}

Yield: 79%. mp: 166--170°C; IR (KBr) ʋ (cm^−1^): 3466, 3234 (N‐H), 1724 (C=O), 1681 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.70--0.90 (1H, m, C~8~‐H), 0.81 (9H, s, *tert*‐butyl CH~3~), 1.07--1.23 (2H, m, spirodecane C~7,9‐ax~‐H), 1.54--1.71 (6H, m, C~7,9‐eq~‐H and C~6,10~‐H), 3.55 (2H, s, spirodecane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.95--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.32 (2H, m, phenyl C~3,5~‐H), 10.30 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 24.11 (spirodecane C~7‐9~), 27.74 (*tert*‐butyl CH~3~), 28.27 (spirodecane C~2~), 32.34 (spirodecane C~8~‐[C]{.ul}), 37.35 (spirodecane C~6,10~), 46.13 (spirodecane C~8~), 66.47 (OCH~2~), 72.64 (spirodecane C~5~), 115.32, 121.81, 129.89 (phenyl C~2‐6~), 158.01 (phenyl C~1~), 167.95 (NHCO), 168.02 (CO). (ESI−) MS *m/z* (%): 375 (\[M‐H\]^−^, 100), 301 (22). Anal. calcd. for C~20~H~28~N~2~O~3~S (376.51): C: 63.80, H: 7.50, N: 7.44. Found: C: 63.86, H: 8.00, N: 7.41.

#### *N*‐\[3‐Oxo‐8‐(trifluoromethyl)‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl\]‐2‐phenoxyacetamide (7e) {#ardp201800330-sec-0190}

Yield: 100%. mp: 131--135°C; IR (KBr) ʋ (cm^−1^): 3468, 3167 (O‐H/N‐H), 1697 (C=O), 1660 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.36--1.52 (2H, m, spirodecane C~6,10‐ax~‐H), 1.69--1.95 (6H, m, C~6,10‐eq~‐H and C~7,9~‐H), 2.10‐2.25 (1H, m, C~8‐ax~‐H), 3.63 (2H, s, spirodecane C~2~‐H), 4.69 (2H, s, OCH~2~), 6.97--7.03 (3H, m, phenyl C~2,4,6~‐H), 7.31--7.35 (2H, m, phenyl C~3,5~‐H), 10.38 (1H, s, NH). ^13^C‐NMR (APT) (DMSO‐*d* ~*6*~/125 MHz): 22.06, 35.25 (spirodecane C~6,7,9,10~), 28.23 (spirodecane C~2~), 39.00 (q, ^2^ *J* ~C‐F~ = 26 Hz, C~8~), 66.46 (OCH~2~), 71.47 (spirodecane C~5~), 115.31, 121.79, 129.94 (phenyl C~2‐6~), 124.80, 128.13 (q, ^1^ *J* ~C‐F~ = 277 Hz, CF~3~), 158.04 (phenyl C~1~), 167.93 (NHCO), 168.19 (CO). (ESI−) MS *m/z* (%): 387 (\[M‐H\]^−^, 100), 313 (20). Anal. calcd. for C~17~H~19~F~3~N~2~O~3~S.2H~2~O (424.43): C: 48.11, H: 5.46, N: 6.60. Found: C: 48.39, H: 5.13, N: 6.79.

#### *N*‐(8‐Phenyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7f) {#ardp201800330-sec-0200}

Yield: 93%. mp: 165--169°C; IR (KBr) ʋ (cm^−1^): 3460, 3253 (N‐H), 1724 (C=O), 1680 (NHC = O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 1.55--1.70 (2H, m, spirodecane C~7,9‐ax~‐H), 1.74--1.94 (6H, m, spirodecane C~7,9‐eq~‐H and C~6,10~‐H), 2.35 (1H, tt, *J* = 13 Hz, 3 Hz, spirodecane C~8~‐H), 3.61 (2H, s, spirodecane C~2~‐H), 4.72 (2H, s, OCH~2~), 6.96--7.07 (3H, m, phenoxy C~2,4,6~‐H), 7.14--7.22 (3H, m, phenyl C~8~‐H and phenoxy C~3,5~‐H), 7.25--7.37 (4H, m, phenyl‐H), 10.36 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 28.34, 30.88 (spirodecane C~6,7,9,10~), 37.30 (spirodecane C~2~), 41.93 (spirodecane C~8~), 66.52 (OCH~2~), 72.17 (spirodecane C~5~), 115.17, 115.35, 121.84, 129.91, 129.96 (phenoxy C~2‐6~), 126.59, 127.00, 128.85, (phenyl C~2‐6~), 146.24 (phenyl C~1~), 158.05 (phenoxy C~1~), 168.00 (NHCO), 168.14 (CO). (ESI−) MS *m/z* (%): 395 (\[M‐H\]^‐^, 100), 321 (12). Anal. calcd. for C~22~H~24~N~2~O~3~S (396.50): C: 66.64, H: 6.10, N: 7.07. Found: C: 66.55, H: 5.99, N: 7.05.

#### *N*‐(3‐Oxo‐1‐thia‐4‐azaspiro\[4.6\]undec‐4‐yl)‐2‐phenoxyacetamide (7g) {#ardp201800330-sec-0210}

Yield: 60%. mp: 115--119°C; IR (KBr) ʋ (cm^−1^): 3462, 3236 (N‐H), 1726 (C=O), 1681 (NHC = O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.32--1.43 (4H, m, C~8,9~‐H), 1.43--1.68 (4H, m, C~7,10~‐H), 1.87 (2H, dd, *J* = 14.5 Hz, 8 Hz, C~6/11~‐H), 1.99 (2H, broad dd, *J* = 14.5 Hz, 8H, C~6/11~‐H), 3.57 (2H, s, C~2~‐H), 4.70 (2H, s, OCH~2~), 6.96--7.01 (3H, m, phenyl C~2,4,6~‐H), 7.29--7.33 (2H, m, phenyl C~3,5~‐H), 10.33 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 22.62, 28.53 (spiroundecane C~6‐11~), 28.60 (spiroundecane C~2~), 66.43 (OCH~2~), 74.79 (spiroundecane C~5~), 115.22, 121.79, 129.90 (phenyl C~2‐6~), 158.06 (phenyl C~1~), 167.42 (NHCO), 168.07 (CO). (ESI+) MS *m/z* (%): 357 (\[M+Na\]^+^, 100), 335 (\[M+H\]^+^, 80), 261 (90). Anal. calcd. for C~17~H~22~N~2~O~3~S (334.43): C: 61.05, H: 6.63, N: 8.38. Found: C: 61.15, H: 6.59, N: 8.72.

#### *N*‐(2‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]non‐4‐yl)‐2‐phenoxyacetamide (7h) {#ardp201800330-sec-0220}

Yield: 80%. mp: 121--125°C; IR (KBr) ʋ (cm^−1^): 3448, 3230 (N‐H), 1728 (C=O), 1685 (NH=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 1.41 (3H, d, *J* = 7 Hz, CH~3~), 1.49--1.62 (4H, m, spirononane C~7,8~‐H), 1.72, 1.80 (1H, 1H, dt, *J* = 13 Hz, 6 Hz, C~6,9~‐H), 1.95--2.15 (2H, m, C~6,9~‐H), 3.92 (1H, q, *J* = 7 Hz, spirononane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.95--6.99 (3H, m, phenyl C~2,4,6~‐H), 7.28--7.32 (2H, m, phenyl C~3,5~‐H), 10.39 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 19.62 (CH~3~), 23.03, 23.10, 38.80 (spirononane C~6‐9~), 38.08 (spirononane C~2~), 66.50 (OCH~2~), 74.68 (spirononane C~5~), 115.23, 121.81, 129.89 (phenyl C~2‐6~), 158.02 (phenyl C~1~), 168.10 (NHCO), 170.57 (CO). (ESI−) MS *m/z* (%): 319 (\[M‐H\]^−^, 100), 245 (8). Anal. calcd. for C~16~H~20~N~2~O~3~S (320.40): C: 59.98, H: 6.29, N: 8.74. Found: C: 59.88, H: 6.21, N: 8.56.

#### *N*‐(2‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7i) {#ardp201800330-sec-0230}

Yield: 94%. mp: 134--136°C; IR (KBr) ʋ (cm^−1^): 3444, 3230 (N‐H), 1728 (C=O), 1687 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.92 (1H, broad q, *J* = 13 Hz, spirodecane C~8‐ax~‐H), 1.39 (3H, d, *J* = 7 Hz, CH~3~), 1.24--1.45 (2H, m, spirodecane C~7,9‐ax~‐H), 1.50 (1H, broad d, *J* = 13 Hz, spirodecane C~8‐eq~‐H), 1.56--1.78 (6H, m, C~6,10~‐H, C~7,9‐eq~‐H), 3.87 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 4.69 (2H, s, OCH~2~), 6.96--7.02 (3H, m, phenyl C~2,4,6~‐H), 7.29--7.34 (2H, m, phenyl C~3,5~‐H), 10.37 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/100 MHz): 19.58 (CH~3~), 22.59, 23.03, 23.80, 36.57, and 36.86 (spirodecane C~6‐10~), 37.75 (spirodecane C~2~), 65.90 (OCH~2~), 70.73 (spirodecane C~5~), 114.72, 121.23, 129.35 (phenyl C~2‐6~), 157.50 (phenyl C~1~), 167.52 (NHCO), 169.97 (CO). (ESI+) MS *m/z* (%): 357 (\[M+Na\]^+^, 100), 335 (\[M+H\]^+^, 85), 247 (75). Anal. calcd. for C~17~H~22~N~2~O~3~S (334.43): C: 61.05, H: 6.63, N: 8.38. Found: C: 61.24, H: 6.46, N: 8.50.

#### *N*‐(2,7‐Dimethyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7j) {#ardp201800330-sec-0240}

Yield: 92%. mp: 132--138°C; IR (KBr) ʋ (cm^−1^): 3383, 3251 (N‐H), 1712 (C=O), 1687 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.62 (1H, qd, *J* = 13 Hz, 3 Hz, spirodecane C~8‐ax~‐H), 0.82 (3H, d, *J* = 7 Hz, C~7~‐CH~3~), 1.29--1.73 (8H, m, spirodecane C~6~‐H, C~7~‐H, C~8‐eq~‐H, C~9~‐H and C~10~‐H), 1.39 (3H, d, *J* = 7 Hz, spirodecane C~2~‐CH~3~), 3.86 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.95--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.32 (2H, m, phenyl C~3,5~‐H), 10.33 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/125 MHz): 19.90 (spirodecane C~2~‐CH~3~), 22.54 (spirodecane C~7~‐CH~3~), 23.12 (spirodecane C~9~), 29.78 (spirodecane C~7~), 37.16 (spirodecane C~2~), 33.06 (spirodecane C~8~), 36.78 (spirodecane C~10~), 46.22 (spirodecane C~6~), 66.41 (OCH~2~), 71.24 (spirodecane C~5~), 115.28, 121.79, 129.91 (phenyl C~2‐6~), 158.00 (phenyl C~1~), 168.03 (NHCO), 170.46 (CO). (ESI+) MS *m/z* (%): 371 (\[M+Na\]^+^, 40), 349 (\[M+H\]^+^, 100), 261 (38). Anal. calcd. for C~18~H~24~N~2~O~3~S (348.45): C: 62.04, H: 6.94, N: 8.04. Found: C: 62.26, H: 6.92, N: 8.56.

#### *N*‐(2,8‐Dimethyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7k) {#ardp201800330-sec-0250}

Yield: 100%. mp: 147--152°C; IR (KBr) ʋ (cm^−1^): 3390, 3259 (N‐H), 1726 (C=O), 1685 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.82 (3H, d, *J* = 6 Hz, spirodecane C~8~‐CH~3~), 0.96--1.25 (3H, m, spirodecane C~7,9‐ax~‐H and C~8~‐H), 1.38 (3H, d, *J* = 7 Hz, spirodecane C~2~‐CH~3~), 1.56--1.85 (6H, m, spirodecane C~6,10~‐H, C~7,9‐eq~‐H), 3.86 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.93--6.99 (3H, m, phenyl C~2,4,6~‐H), 7.26--7.32 (2H, m, phenyl C~3,5~‐H), 10.31 (1H, s, NH). ^13^C‐NMR (proton decoupled; DMSO‐*d* ~*6*~/100 MHz): 19.65 (spirodecane C~2~‐CH~3~), 21.81 (spirodecane C~8~‐CH~3~), 30.38 (spirodecane C~8~), 31.13, 31.62, 37.53 (spirodecane C~6,7,9,10~), 36.65 (spirodecane C~2~), 65.96 (OCH~2~), 70.65 (spirodecane C~5~), 114.69, 114.78, 121.20, 121.29, 129.42 (phenyl C~2‐6~), 157.58 (phenyl C~1~), 166.69, 167.59 (NHCO), 170.11 (CO). (ESI−) MS *m/z* (%): 347 (\[M‐H\]^−^, 100), 259 (25). Anal. calcd. for C~18~H~24~N~2~O~3~S (348.45): C: 62.04, H: 6.94, N: 8.04. Found: C: 61.61, H: 6.89, N: 8.15.

#### *N*‐(2‐Methyl‐8‐*tert*‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7l) {#ardp201800330-sec-0260}

Yield: 100%. mp: 155--158°C; IR (KBr) ʋ (cm^−1^): 3444, 3251 (N‐H), 1722 (C=O), 1693 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.70--0.89 (1H, m, spirodecane C~8~‐H), 0.80 (9H, s, *tert*‐butyl CH~3~), 1.04--1.24 (2H, m, spirodecane C~7,9‐ax~‐H), 1.38 (3H, d, *J* = 7 Hz, spirodecane CH~3~), 1.54--1.79 (6H, m, spirodecane C~7,9‐eq~‐H, C~6,10~‐H), 3.85 (H, q, *J* = 7 Hz, spirodecane C~2~‐H), 4.68 (2H, s, OCH~2~), 6.94--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.27--7.31 (2H, m, phenyl C~3,5~‐H), 10.34 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/100 MHz): 19.50 (spirodecane C~2~‐CH~3~), 23.38, 23.82, 36.90, and 37.60 (spirodecane C~6,7,9,10~), 27.16 (*tert*‐butyl CH~3~), 31.77 (*tert‐*butyl C), 36.60 (spirodecane C~2~), 45.50 (spirodecane C~8~), 65.90 (OCH~2~), 70.73 (spirodecane C~5~), 114.61, 114.76, 121.24, 129.33 (phenyl C~2‐6~), 157.47, 157.50 (phenyl C~1~), 166.50, 167.43 (NHCO), 170.04 (CO). (ESI+) MS *m/z* (%): 413 (\[M+Na\]^+^, 75), 391 (\[M+H\]^+^, 100), 303 (40). Anal. calcd. for C~21~H~30~N~2~O~3~S (390.53): C: 64.58, H: 7.74, N: 7.17. Found: C: 64.04, H: 7.75, N: 7.27.

#### *N*‐\[2‐Methyl‐3‐oxo‐8‐(trifluoromethyl)‐1‐thia‐4‐azaspiro\[4.5\]‐dec‐4‐yl\]‐2‐phenoxyacetamide (7m) {#ardp201800330-sec-0270}

Yield: 100%. mp: 78--81°C; IR (KBr) ʋ (cm^−1^): 3444, 3196 (O‐H/N‐H), 1716 (C=O), 1685 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 1.29--1.53 (2H, m, spirodecane C~6,10‐ax~‐H), 1.39 (3H, d, *J* = 7 Hz, spirodecane C~2~‐CH~3~), 1.66--1.99 (6H, m, spirodecane C~6,10‐eq~‐H and C~7,9~‐H), 2.08--2.25 (1H, m, C~8~‐H), 3.92 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 4.66 (2H, s, OCH~2~), 6.94--7.00 (3H, m, phenyl C~2,4,6~‐H), 7.28--7.32 (2H, m, phenyl C~3,5~‐H), 10.40 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/100 MHz): 19.51 (CH~3~), 21.43, 21.86, 34.90, 35.71 (spirodecane C~6,7,9,10~), 36.73 (spirodecane C~2~), 39.49 (q,^2^ *J* ~C‐F~ = 26 Hz, spirodecane C~8~), 65.99 (OCH~2~), 69.67 (spirodecane C~5~), 114.83, 121.32, 129.47 (phenyl C~2‐6~), 127.65 (q,^1^ *J* ~C‐F~ = 277 Hz, CF~3~), 157.57 (phenyl C~1~), 167.71 (NHCO), 170.08 (CO). (ESI+) MS *m/z* (%): 425 (\[M+Na\]^+^, 32), 403 (\[M+H\]^+^, 100), 315 (72). Anal. calcd. for C~18~H~21~F~3~N~2~O~3~S.0.5H~2~O (411.43): C: 52.49, H: 5.34, N: 6.80. Found: C: 52.34, H: 5.52, N: 6.75.

#### *N*‐(2‐Methyl‐8‐phenyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]dec‐4‐yl)‐2‐phenoxyacetamide (7n) {#ardp201800330-sec-0280}

Yield: 100%. mp: 78--80°C; IR (KBr) ʋ (cm^−1^): 3334, 3197 (N‐H), 1712 (C=O), 1676 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 1.43 (3H, d, *J* = 8 Hz, spirodecane C~2~‐CH~3~), 1.48--1.71 (2H, m, spirodecane C~7,9‐ax~‐H), 1.73--2.03 (6H, m, spirodecane C~7,9‐eq~‐H, C~6,10~‐H), 2.35 (1H, broad t, *J* = 13 Hz, spirodecane C~8~‐H), 3.93 (1H, q, *J* = 8 Hz, spirodecane C~2~‐H), 4.73 (2H, s, OCH~2~), 6.95--7.06 (3H, m, phenoxy C~2,4,6~‐H), 7.14--7.21 (3H, m, phenoxy C~3,5~‐H and C~8~‐phenyl‐H), 7.25--7.37 (4H, m, phenyl‐H), 10.44 (1H, s, NH). ^13^C‐NMR (proton decoupled) (DMSO‐*d* ~*6*~/100 MHz): 18.46 (spirodecane C~2~‐CH~3~), 30.12, 30.68, 36.85, 37.71 (spirodecane C~6,7,9,10~), 36.69 (spirodecane C~2~), 41.36 (spirodecane C~8~), 65.96 (OCH~2~), 70.26 (spirodecane C~5~), 114.79, 121.28, 129.40 (phenoxy C~2‐6~), 126.03, 128.30 (phenyl C~2‐6~), 145.72 (phenyl C~1~), 157.52 (phenoxy C~1~), 167.57 (NHCO), 170.07 (CO). (ESI−) MS *m/z* (%): 409 (\[M‐H\]^−^, 100), 321 (10). Anal. calcd. for C~23~H~26~N~2~O~3~S.C~2~H~5~OH (456.59): C: 65.76, H: 7.06, N: 6.14. Found: C: 65.48, H: 6.79, N: 6.50.

#### *N*‐(2‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]nonan‐4‐yl)‐3‐phenylpropanamide (8a) {#ardp201800330-sec-0290}

Yield: 89%. mp: 190--193°C; IR (KBr) ʋ (cm^−1^): 3221, 3196 (N‐H), 1716 (C=O), 1670 (NHC=O). ^1^H‐NMR (DMSO‐d~6~/500 MHz): 1.04--1.82 (8H, m, spirononane C~6‐9~‐H), 2.49--2.53 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.61 (2H, s, spirononane C~2~‐H), 7.18--7.29 (5H, m, phenyl C~2‐6~‐H), 9.97 (1H, s, NH). Anal. calcd. for C~16~H~20~N~2~O~2~S (304.40): C: 63.13, H: 6.62, N: 9.20. Found: C: 63.08, H: 6.71, N: 9.23.

#### *N*‐(3‐Oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8b) {#ardp201800330-sec-0300}

Yield: 100%. mp: 98--99°C; IR (KBr) ʋ (cm^−1^): 3354, 3167 (N‐H), 1703 (C=O), 1670 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.88--1.62 (10H, m, spirodecane C~6‐10~), 2.49--2.52 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.52 (2H, s, spirodecane C~2~‐H), 7.16--7.29 (5H, m, phenyl C~2‐6~‐H), 9.91 (1H, s, NH). Anal. calcd. for C~17~H~22~N~2~O~2~S. 0.5C~2~H~5~OH (321.43): C: 63.31, H: 7.38, N: 8.20. Found: C: 62.78, H:6.81, N: 8.59.

#### *N*‐(8‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8c) {#ardp201800330-sec-0310}

Yield: 100%. mp: 102--105°C; IR (KBr) ʋ (cm^−1^): 3408, 3232 (N‐H), 1705 (C=O), 1674 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.81--1.60 (9H, m, spirodecane C~6‐10~), 0.84 (3H, d, *J* = 7 Hz, CH~3~), 2.49--2.51 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.53 (2H, s, spirodecane C~2~‐H), 7.16--7.28 (5H, m, phenyl C~2‐6~‐H), 9.91 (1H, s, NH). Anal. calcd. for C~18~H~24~N~2~O~2~S. 0.5C~2~H~5~OH (355.46): C: 64.61, H: 7.79, N: 7.73. Found: C: 64.13, H: 7.35, N: 8.03.

#### *N*‐(8‐Ethyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8d) {#ardp201800330-sec-0320}

Yield: 97%. mp: 145--147°C; IR (KBr) ʋ (cm^−1^): 3396, 3230 (N‐H), 1705 (C=O), 1674 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.83--1.62 (9H, m, spirodecane C~6‐10~), 0.84 (3H, t, *J* = 7 Hz, CH~3~), 1.15 (2H, qu, *J* = 7 Hz, spirodecane C~8~‐CH~2~), 2.49--2.52 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.52 (2H, s, spirodecane C~2~‐H), 7.15--7.28 (5H, m, phenyl C~2‐6~‐H), 9.91 (1H, s, NH). Anal. calcd. for C~19~H~26~N~2~O~2~S. 0.5C~2~H~5~OH (369.48): C: 65.01, H:7.51, N: 7.58. Found: C: 65.16, H:7.52, N: 7.68.

#### *N*‐(3‐Oxo‐8‐propyl‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8e) {#ardp201800330-sec-0330}

Yield: 100%. mp: 102--107°C; IR (KBr) ʋ (cm^−1^): 3383, 3230 (N‐H), 1705 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.86 (3H, t, *J* = 7 Hz, CH~3~), 0.99--1.61 (9H, m, spirodecane C~6‐10~), 1.05 (2H, t, *J* = 7 Hz, spirodecane C~8~‐CH~2~), 1.23--1.31 (2H, m, spirodecane C~8~‐CH~2~), 2.49--2.52 (m, CH~2~, and DMSO‐d~6~), 2.87 (2H, t, *J* = 7 Hz, CH~2~), 3.52 (2H, s, spirodecane C~2~‐H), 7.17--7.29 (5H, m, phenyl C~2‐6~‐H), 9.91 (1H, s, NH). Anal. calcd. for C~20~H~28~N~2~O~2~S. 0.5C~2~H~5~OH (383.51): C: 65.76, H: 8.15, N: 7.30. Found: C: 65.58, H: 7.86, N: 7.29.

#### *N*‐(8‐*tert*‐Butyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8f) {#ardp201800330-sec-0340}

Yield: 100%. mp: 154--155°C; IR (KBr) ʋ (cm^−1^): 3385, 3253 (N‐H), 1701 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.72--1.64 (9H, m, spirodecane C~6‐10~), 0.82 (9H, s, CH~3~), 2.49--2.52 (m, CH~2~, and DMSO‐d~6~), 2.87 (2H, t, *J* = 7 Hz, CH~2~), 3.52 (2H, s, spirodecane C~2~‐H), 7.17--7.29 (5H, m, phenyl‐CH), 9.91 (1H, s, NH). Anal. calcd. for C~21~H~30~N~2~O~2~S. 0.5C~2~H~5~OH (397.54): C: 66.46, H: 8.37, N: 7.05. Found: C: 66.84, H: 8.14, N: 7.04.

#### *N*‐\[3‐Oxo‐(8‐trifluoromethyl)‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl\]‐3‐phenylpropanamide (8g) {#ardp201800330-sec-0350}

Yield: 94%. mp: 94--100°C; IR (KBr) ʋ (cm^−1^): 3392, 3186 (N‐H), 1697 (C=O), 1670 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.39--2.09 (9H, m, spirodecane C~6‐10~), 2.49--2.53 (m, CH~2~ and DMSO‐d~6~), 2.88 (2H, t, *J* = 7 Hz, CH~2~), 3.59 (2H, s, spirodecane C~2~‐H), 7.16--7.31 (5H, m, phenyl‐CH), 10.00 (1H, s, NH). Anal. calcd. for C~18~H~21~F~3~N~2~O~2~S. 0.5H~2~O (395.43): C: 54.68, H: 5.82, N: 7.08. Found: C: 54.71, H: 5.97, N: 7.12.

#### *N*‐(8*‐*Phenyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8h) {#ardp201800330-sec-0360}

Yield: 100%. mp: 194--196°C; IR (KBr) ʋ (cm^−1^): 3300, 3223 (N‐H), 1726 (C=O), 1681 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.04--2.31 (9H, m, spirodecane C~6‐10~), 2.49--2.56 (m, CH~2~ and DMSO‐d~6~), 2.90 (2H, t, *J* = 7 Hz, CH~2~), 3.58 (2H, s, spirodecane C~2~‐H), 7.19--7.34 (10H, m, phenyl‐CH), 10.00 (1H, s, NH). Anal. calcd. for C~23~H~26~N~2~O~2~S (394.52): C: 70.02, H: 6.64, N: 7.10. Found: C: 69.99, H: 6.58, N: 7.19.

#### *N*‐(2‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.4\]nonan‐4‐yl)‐3‐phenylpropanamide (8i) {#ardp201800330-sec-0370}

Yield: 90%. mp: 169--171°C; IR (KBr) ʋ (cm^−1^): 3380, 3190 (N‐H), 1716 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.04--1.88 (8H, m, spirononane C~6‐9~‐H), 1.40 (3H, d, *J* = 7 Hz, CH~3~), 2.49--2.53 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.90 (1H, q, *J* = 7 Hz, spirononane C~2~‐H), 7.18--7.29 (5H, m, phenyl‐CH), 10.02 (1H, s, NH). Anal. calcd. for C~17~H~22~N~2~O~2~S (318.43): C: 64.12, H: 6.96, N: 8.80. Found: C: 64.16, H: 6.80, N: 8.87.

#### *N*‐(2‐Methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8j) {#ardp201800330-sec-0380}

Yield: 100%. mp: 141--145°C; IR (KBr) ʋ (cm^−1^): 3390, 3290 (N‐H), 1716 (C=O), 1681 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/400 MHz): 0.86--1.59 (10H, m, spirodecane C~6‐10~), 1.35 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.46--2.54 (m, CH~2~, and DMSO‐d~6~), 2.85 (2H, t, *J* = 7 Hz, CH~2~), 3.80 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.14--7.28 (5H, m, phenyl C~2‐6~‐H), 9.95 (1H, s, NH). ^13^C‐NMR (DEPT) (DMSO‐*d* ~*6*~/400 MHz): 19.68 (CH~3~), 22.59, 23.40, 23.74, 30.66, 34.67 (spirodecane C~2‐6~ and 2CH~2~), 36.62 (spirodecane C~2~), 70.55 (spirodecane C~5~), 125.99, 128.18, 128.35 (phenyl C~2‐6~), 140.52 (phenyl C~1~), 170.04 (amide CO), 170.77 (spirodecane CO). Anal. calcd. for C~18~H~24~N~2~O~2~S (332.46): C: 65.03, H: 7.28, N: 8.43. Found: C: 64.77, H: 7.11, N: 8.49.

#### *N*‐(2,8‐Dimethyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8k) {#ardp201800330-sec-0390}

Yield: 100%. mp: 68--71°C; IR (KBr) ʋ (cm^−1^): 3421, 3261 (N‐H), 1701 (C=O), 1670 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.79--1.60 (9H, m, spirodecane C~6‐10~), 0.84 (3H, d, *J* = 7 Hz, CH~3~), 1.37 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.49--2.53 (m, CH~2~, and DMSO‐d~6~), 2.87 (2H, t, *J* = 7 Hz, CH~2~), 3.83 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.16--7.29 (5H, m, phenyl C~2‐6~‐H), 9.96 (1H, s, NH). Anal. calcd. for C~19~H~26~N~2~O~2~S. 0.5H~2~O (346.48): C: 64.22, H: 7.88, N: 7.88. Found: C: 63.98, H: 7.55, N: 8.04.

#### *N*‐(8‐Ethyl‐2‐methyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8l) {#ardp201800330-sec-0400}

Yield: 94%. mp: 144--146°C; IR (KBr) ʋ (cm^−1^): 3310, 3186 (N‐H), 1720 (C=O), 1674 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.81--1.63 (9H, m, spirodecane C~6‐10~), 0.84 (3H, t, *J* = 7 Hz, CH~3~), 1.16 (2H, qu, *J* = 7 Hz, spirodecane C~8~‐CH~2~), 1.37 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.49--2.51 (m, CH~2~, and DMSO‐d~6~), 2.87 (2H, t, *J* = 7 Hz, CH~2~), 3.83 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.17--7.29 (5 H, m, phenyl C~2‐6~‐H), 9.97 (1H, s, NH). Anal. calcd. for C~20~H~28~N~2~O~2~S (360.51): C: 66.63, H: 7.83, N: 7.77. Found: C: 66.68, H: 7.55, N: 7.90.

#### *N*‐(2‐Methyl‐3‐oxo‐8‐propyl‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8m) {#ardp201800330-sec-0410}

Yield: 93%. mp: 157--159°C; IR (KBr) ʋ (cm^−1^): 3388, 3188 (N‐H), 1724 (C=O), 1670 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.86 (3H, t, *J* = 7 Hz, CH~3~), 0.99--1.61 (9H, m, spirodecane C~6‐10~), 1.27 (2H, m, spirodecane C~8~‐CH~2~), 1.37 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.49--2.52 (m, CH~2~, and DMSO‐d~6~), 2.86 (2H, t, *J* = 7 Hz, CH~2~), 3.82 (1H, q, *J* = 7 Hz, spd C~2~‐H), 7.17--7.29 (5 H, m, phenyl C~2‐6~‐H), 9.96 (1 H, s, NH). Anal. calcd. for C~21~H~30~N~2~O~2~S (374.54): C: 67.34, H: 8.07, N: 7.48. Found: C: 67.21, H: 7.76, N: 7.57.

#### *N*‐(2‐Methyl‐8‐*tert*‐butyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8n) {#ardp201800330-sec-0420}

Yield: 100%. mp: 122--123°C; IR (KBr) ʋ (cm^−1^): 3385, 3125 (N‐H), 1701 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 0.69--1.62 (9H, m, spirodecane C~6‐10~), 0.82 (9H, s, CH~3~), 1.37 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.49--2.52 (m, CH~2~ and DMSO‐d~6~), 2.87 (2H, t, *J* = 7 Hz, CH~2~), 3.82 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.17--7.29 (5H, m, phenyl C~2‐6~‐H), 9.96 (1H, s, NH). Anal. calcd. for C~22~H~32~N~2~O~2~S.H~2~O (406.56): C: 64.93, H: 8.36, N: 6.88. Found: C: 64.73, H: 8.16, N: 6.98.

#### *N*‐\[2‐Methyl‐3‐oxo‐(8‐trifluoromethyl)‐1‐thia‐4‐azaspiro\[4.5\]‐decan‐4‐yl\]‐3‐phenylpropanamide (8o) {#ardp201800330-sec-0430}

Yield: 95%. mp: 126--130°C; IR (KBr) ʋ (cm^−1^): 3390, 3196 (N‐H), 1697 (C=O), 1660 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.27--2.09 (9H, m, spirodecane C~6‐10~), 1.39 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.47--2.53 (m, CH~2~ and DMSO‐d~6~), 2.88 (2H, t, *J* = 7 Hz, CH~2~), 3.89 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.15--7.31 (5H, m, phenyl C~2‐6~‐H), 10.06 (1H, s, NH). Anal. calcd. for C~19~H~23~F~3~N~2~O~2~S (418.45): C: 54.53, H: 6.02, N: 6.69. Found: C: 54.61, H: 6.11, N: 6.91.

#### *N*‐(2‐Methyl‐8*‐*phenyl‐3‐oxo‐1‐thia‐4‐azaspiro\[4.5\]decan‐4‐yl)‐3‐phenylpropanamide (8p) {#ardp201800330-sec-0440}

Yield: 96%. mp: 206--207°C; IR (KBr) ʋ (cm^−1^): 3350, 3182 (N‐H), 1720 (C=O), 1668 (NHC=O). ^1^H‐NMR (DMSO‐*d* ~*6*~/500 MHz): 1.04--2.31 (9H, m, spirodecane C~6‐10~), 1.41 (3H, d, *J* = 7 Hz, C~2~‐CH~3~), 2.49--2.56 (m, CH~2~, and DMSO‐d~6~), 2.90 (2 H, t, *J* = 7 Hz, CH~2~), 3.89 (1H, q, *J* = 7 Hz, spirodecane C~2~‐H), 7.19--7.32 (10H, m, phenyl‐CH), 10.05 (1H, s, NH). Anal. calcd. for C~24~H~28~N~2~O~2~S (408.55): C: 70.55, H: 6.91, N: 6.86. Found: C: 70.57, H: 6.79, N: 6.94.

4.2. Antiviral activity assays {#ardp201800330-sec-0450}
------------------------------

Cytopathic effect (CPE) reduction assays were performed to determine antiviral activity against human coronavirus 229E and influenza A/H1N1, A/H3N2, and B virus. The HCoV‐229E stock was obtained from ATCC (VR‐740™) and expanded in human embryonic lung (HEL) 299 fibroblast cells (ATCC CCL‐137™). For the CPE reduction assay, HEL cells were seeded in 96‐well plates and grown for 6 days until they reached confluence.

The influenza virus strain A/HK/7/87 (A/H3N2) was a kind gift from J. Neyts (Leuven, Belgium), whereas the clinical isolates A/Ned/378/05 (A/H1N1) and B/Ned/537/05 were generously provided by R. Fouchier (Rotterdam, The Netherlands). Virus stocks were prepared in 10‐day‐old embryonated hen eggs; the clinical isolates first underwent one passage in eggs. The influenza CPE reduction assays were performed in Madin‐Darby canine kidney (MDCK) cells (a kind gift from M. Matrosovich, Marburg, Germany) which were seeded 1 day before infection at 7500 cells per well in 96‐well plates.

The cells were infected with the respective viruses at a multiplicity of infection of 100 (HCoV‐229E) or 50 (influenza virus) "50% cell culture infective doses" (CCID~50~) per well in the presence of serial dilutions of the test compounds. After five (HCoV‐229E) or three (influenza virus) days incubation at 35°C, virus‐induced CPE and compound cytotoxicity (in uninfected cells) were determined by microscopic scoring. Antiviral activity was expressed as EC~50~ or concentration showing 50% effectivity; cytotoxicity was expressed as MCC, that is, minimum cytotoxic concentration producing minimal changes in cell morphology. For HCoV‐229E, **K22** \[(*Z*)‐*N*‐\[3‐\[4‐(4‐bromophenyl)‐4‐hydroxypiperidin‐1‐yl\]‐3‐oxo‐1‐phenylprop‐1‐en‐2‐yl\]benzamide; purchased from ChemDiv\][14](#ardp201800330-bib-0014){ref-type="ref"} was included as a reference compound. The following reference compounds were included for influenza virus: ribavirin (Virazole from ICN Pharmaceuticals, Costa, CA), rimantadine and amantadine (both from Sigma‐Aldrich, Belgium). Compounds showing anti‐HCoV activity were evaluated in 3--4 independent experiments.
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